Please assess the completion status of the following clinical trial:

Trial Title: External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy proven prostate cancer within last 12 months. Pathology must be reviewed at M.D. Anderson Cancer Center (MDACC).~2. 1992 American Joint Committee on Cancer (AJCC) clinical stage T1c-2b on digital rectal exam with biopsy Gleason sum of 7 and Prostate-Specific Antigen (PSA) \< 20 ng/mL (i.e. PSA 19.99 ng/mL or less)~3. 1992 AJCC clinical stage T2b on physical exam with biopsy Gleason sum of 7 or less and/or PSA \< 20 ng/ml~4. 1992 AJCC clinical stage T1c-2b on digital rectal exam with biopsy Gleason sum of 7 or less and PSA \> 10 but less than 20 ng/ml (i.e. 10.01-19.99 ng/mL). PSA used for protocol eligibility should be obtained within 30 days of protocol enrollment.~5. No evidence of metastatic disease on bone scan within 3 months of study enrollment.~6. No evidence of metastatic disease on pelvic computed tomography (CT) or magnetic resonance imaging (MRI) within 3 months of study enrollment.~7. Zubrod performance status \< 2.~8. Must be able to understand protocol and adhere to follow-up initially at 3 months post-radiation and then at 6 month intervals for first two years and annually thereafter.~9. Patient must be able to undergo adequate daily trans-abdominal ultrasound localization (B.A.T.) or other image-guided localization of the prostate during radiation course.~10. Patients will be allowed to participate in other protocols if they are eligible and the other protocols do not interfere with participation in this protocol.~Exclusion Criteria:~1. Patients who do not meet the inclusion criteria. Specifically, patients with all the following features: clinical T1c-2a and Gleason sum of 6 and PSA \</= 10 ng/ml. Patients with one or more of the following features: clinical T2c, or Gleason 8-10, or PSA \> 20 ng/ml are not eligible.~2. Prior androgen suppression therapy. (Prior finasteride and saw palmetto allowed but must be discontinued prior to enrollment. Biopsy and PSA must be documented prior to finasteride use.)~3. Previous or concurrent malignancies other than basal or squamous cell skin cancers unless disease-free for 5 years or more.~4. Prior pelvic radiation or chemotherapy. Patients who received chemotherapy for non-prostate cancer malignancies over 5 years prior will be eligible.~5. Prior or planned radical prostate surgery.~6. Patients with clinical evidence or biopsy-proven extracapsular extension, seminal vesicle involvement, or lymph node involvement will be excluded. Patients with radiographic evidence of nodal or bone metastasis will be excluded.~7. Other histologies such as small cell carcinoma, sarcomatoid or ductal variants are not eligible.~8. Patients with any Gleason grade 5 disease on biopsy will not be eligible.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RT Group 1 (Type: ACTIVE_COMPARATOR): Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
- RT Group 2 + Hormone Therapy (Type: ACTIVE_COMPARATOR): Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)

Based on this trial design, predict the completion outcome and termination type (if applicable).